Integer Holdings Corporation Reports Third Quarter 2026 Results

PLANO, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended October 2, 2026.

Third Quarter 2026 Highlights (compared to Third Quarter 2025, except as noted) * Sales decreased 3.9% to $450 million. Organic sales decreased 2.2%. * GAAP operating income from continuing operations totaled $28 million, a decrease of $28 million or 50%. Non-GAAP adjusted operating income totaled $66 million, a decrease of $20 million or 23%. * GAAP income from continuing operations totaled $15 million, a decrease of $25 million or 62%. Non-GAAP adjusted net income totaled $46 million, a decrease of $17 million or 27%. * GAAP diluted EPS from continuing operations totaled $0.43, a decrease of $0.68 or 61%. Non-GAAP adjusted EPS totaled $1.34, a decrease of $0.45 or 25%. * Adjusted EBITDA totaled $88 million, a decrease of $18 million or 17%. * From the end of 2025, total debt increased $34 million to $1.219 billion and Non-GAAP net total debt increased $33 million to $1.223 billion, resulting in a leverage ratio of 3.3 times adjusted EBITDA as of October 2, 2026. As previously announced, given Integer’s pending acquisition by an affiliate of investment funds managed by KKR (the “Transaction”) pursuant to the Agreement and Plan of Merger, dated as of August 2, 2026, by and among Integer, Armstrong Parent, Inc. (“Parent”), and Armstrong Bidco, Inc. (the “Merger Agreement”), the Company is not providing a financial outlook and will not host a conference call to discuss its third quarter 2026 financial results. On September 29, 2026, the Company received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and on October 21, 2026, Integer's stockholders approved the adoption of the Merger Agreement. The Transaction is anticipated to close by the end of 2026, subject to the satisfaction or waiver of the remaining customary closing conditions specified in the Merger Agreement, including receipt of required regulatory approvals.